Optiver Holding
RNAC icon

Optiver Holding’s Cartesian Therapeutics RNAC Stock Holding History

Optiver Holding’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-104
Closed -$640 – 3039
2026
Q1 		$640 Buy
104
+24
+30% +$171 ﹤0.01% 2135
2025
Q4 		$577 Hold
80
– – ﹤0.01% 2283
2025
Q3 		$818 Buy
+80
New +$899 ﹤0.01% 2522

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Optiver Holding's RNAC Position: Q2 2026 in Review

Optiver Holding sold out of Cartesian Therapeutics (RNAC) in Q2 2026, closing a stake of 104 shares — an estimated $640 sold.

Optiver Holding first reported a position in RNAC in Q3 2025 and held it in 3 quarters. The position peaked at $818 in Q3 2025. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Optiver Holding reported no remaining Cartesian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Optiver Holding sold 104 Cartesian Therapeutics shares in Q2 2026, an estimated $640.
  • Optiver Holding first reported a position in Cartesian Therapeutics in Q3 2025 and held it in 3 quarters.
  • Optiver Holding's Cartesian Therapeutics position peaked at $818 in Q3 2025.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.